(Q38612645)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

meta-analysis

0 references

title

Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

15

Takeshi Kaneko

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1

Nobuyuki Horita

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

9

Kenjiro Nagai

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

6

Ken Tashiro

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

7

Yuji Shibata

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

8

Hiroki Watanabe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

11

Kentaro Nakashima

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

12

Ryota Ushio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

14

Makoto Kudo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

4

Toshinori Tsukahara

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

13

Masaharu Shinkai

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

5

Hideyuki Nagakura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Masaki Yamamoto

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Miyo Inoue

series ordinal

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

21 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

15437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

27 February 2020

copyright license

start time

21 October 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Relapsed small cell lung cancer: treatment options and latest developments

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Third-line chemotherapy in small-cell lung cancer: an international analysis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Second-line chemotherapy for small-cell lung cancer (SCLC).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Who is at high risk for lung cancer? Population-level and individual-level perspectives

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

A phase II study of topotecan in patients with relapsed small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Measuring inconsistency in meta-analyses

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4614251

Probable Inference, the Law of Succession, and Statistical Inference

31 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSREP15437

Synthesis of median survival time in meta-analysis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26486755

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Outcome and prognostic factors in patients with small cell lung cancer who receive third-line chemotherapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26486755

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26486755

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SREP15437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

27 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

PubMed publication ID

26486755

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486755%20AND%20SRC:MED&resulttype=core&format=json